263009-01-4

Basic information

• Product Name: 4-N-Benzoyl-2'-O-[1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl]cytidine
• Synonyms: 4-N-Benzoyl-2'-O-[1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl]cytidine
• CAS NO: 263009-01-4
• Molecular Weight: 585.057
• Mol File: 263009-01-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-N-Benzoyl-2'-O-[1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl]cytidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N-Benzoyl-2'-O-[1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl]cytidine(263009-01-4)
• EPA Substance Registry System: 4-N-Benzoyl-2'-O-[1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl]cytidine(263009-01-4)

Safety Data

• Hazardous Substances Data: 263009-01-4(Hazardous Substances Data)

Upstream product

• 113759-96-9 1-(4-chlorophenyl)piperidin-4-one 
• 119836-12-3 4-hydroxy-1-(4-chlorophenyl)piperidine 
• 106-47-8 4-chloro-aniline 
• 72548-31-3 1,5-Dichloropentan-3-ol 
• 3592-25-4 1,5-dichloropentan-3-one 
• 263008-89-5 1-(4-Chlorophenyl)-4,4-diethoxypiperidine 
• 263008-90-8 1-(4-Chlorophenyl)-4-ethoxy-1,2,5,6-tetrahydropyridine 
• 69304-43-4 1-[3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-β-D-ribofuranosyl]-N⁴-benzoylcytosine 
• 13089-48-0 N₄-benzoylcytidine 
• 908140-96-5 N-(1-{(2R,3R,3aR,9aR)-3-[1-(4-Chloro-phenyl)-4-ethoxy-piperidin-4-yloxy]-5,5,7,7-tetraisopropyl-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl}-2-oxo-1,2-dihydro-pyrimidin-4-yl)-benzamide 

Downstream Products

• 113759-96-9 1-(4-chlorophenyl)piperidin-4-one 
• 13089-48-0 N₄-benzoylcytidine 
• 263009-02-5 2'-O-[1-(4-Chlorophenyl)-4-ethoxypiperidin-4-yl]cytidine 
• 908141-01-5 N-(1-{5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-3-[1-(4-chloro-phenyl)-4-ethoxy-piperidin-4-yloxy]-4-hydroxy-tetrahydro-furan-2-yl}-2-oxo-1,2-dihydro-pyrimidin-4-yl)-benzamide 

Relevant articles and documents

Large-scale synthesis of "Cpep" RNA monomers and their application in automated RNA synthesis

Small interfering RNAs (siRNA) are the latest candidates for oligonucleotide-based therapeutics. Should siRNA be successful in clinical trials, a huge demand for synthetic RNA is anticipated. We believe that 1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl (Cpep